Novel Triple-dose Tuberculosis Retreatment Regimen

Category Primary study
Registry of Trialsclinicaltrials.gov
Year 2021
To determine if a high-dose first-line regimen is non-inferior (non-inferiority margin 10%) in terms of safety to the same regimen at regular dosing, in previously treated patients with rifampicin-susceptible recurrent Tuberculosis (TB).
Epistemonikos ID: fb468220504f15e0cb9511942e606cb9b8571ea6
First added on: May 07, 2024